TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20473734

Group type: EXPERIMENTAL
Intervention: Combined therapy with Jinlong Capsule (JLC) and transcatheter arterial chemoembolization (TACE)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE) only
Number of subjects: 98
Study: 19808281

Group type: EXPERIMENTAL
Intervention: Additional intervention (repetitive education and telephone monitoring)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study: 17002635

Group type: EXPERIMENTAL
Intervention: S-303 treated RBCs after a single transfusion (Study 1A)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: S-303 treated RBCs after multiple transfusions (Study 1B)
Number of subjects: 99

Group type: COMPARATOR
Intervention: S-303 RBCs (Study 1C)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional RBCs (Study 1C)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: S-303 RBCs (Studies 1A and 1B)
Number of subjects: 99
Study: 12728024

Group type: EXPERIMENTAL
Intervention: Operative treatment (posterior or anterior arthrodesis and instrumentation)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Nonoperative treatment (application of a body cast or orthosis)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study: 10834683

Group type: EXPERIMENTAL
Intervention: Sodium citrate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 20
Study: 8772681

Group type: EXPERIMENTAL
Intervention: c7E3 Fab (antiplatelet IIb/IIIa receptor antibody)
Number of subjects: 2038
Study: 1597603

Group type: EXPERIMENTAL
Intervention: Fixed-standard discrimination task with a 500-ms interstimulus interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random-standard discrimination task with an 8-s interstimulus interval
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Identification task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modulation rates above 100 Hz using 500- to 1600-Hz noise band
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General modulation rate perception
Number of subjects: 0
Study: 6321195

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Captopril + Propranolol
Number of subjects: 10
Study: 29458237

Group type: EXPERIMENTAL
Intervention: Irinotecan (80 mg/m2, days 1 and 8) plus capecitabine (1,000 mg/m2 twice a day, days 1-14)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Capecitabine alone (1,250 mg/m2 twice a day, days 1-14)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Irinotecan plus capecitabine in triple-negative breast cancer (TNBC, n=90)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Capecitabine alone in triple-negative breast cancer (TNBC, n=90)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Irinotecan plus capecitabine
Number of subjects: 221

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 221
Study: 29393675

Group type: EXPERIMENTAL
Intervention: Dual-hormone artificial pancreas
Number of subjects: 35

Group type: COMPARATOR
Intervention: Single-hormone artificial pancreas
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dual-hormone artificial pancreas (hypoglycemia awareness)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Single-hormone artificial pancreas (hypoglycemia awareness)
Number of subjects: 35
Study: 26741052

Group type: EXPERIMENTAL
Intervention: Topical naltrexone (1 drop, 4 drops) at dosages of 1 × 10(‐6) M, 5 × 10(‐6) M, 1 × 10(‐5) M, 5 × 10(‐5) M
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (1 drop)
Number of subjects: 20
Study: 25005652

Group type: EXPERIMENTAL
Intervention: Combination treatment (varenicline + nicotine patch)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Varenicline alone
Number of subjects: 446
Study: 23270509

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care and standard care
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 88
Study: 21062129

Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg) plus Ivermectin (200 μg/kg)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg) plus Ivermectin (200 μg/kg)
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg) plus placebo
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg) plus placebo
Number of subjects: 548

Group type: COMPARATOR
Intervention: Ivermectin (200 μg/kg)
Number of subjects: 548
Study: 17958720

Group type: EXPERIMENTAL
Intervention: Anti-reflux stent (n = 24, group 2)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard stent (n = 25, group 1)
Number of subjects: 49
Study: 15736010

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 139

Group type: COMPARATOR
Intervention: Macrolides
Number of subjects: 139
Study: 12492193

Group type: EXPERIMENTAL
Intervention: Balsalazide 6.75 g/day
Number of subjects: 173

Group type: COMPARATOR
Intervention: Mesalamine 2.4 g/day
Number of subjects: 173
Study: 9818039

Group type: EXPERIMENTAL
Intervention: Harmonic imaging (3.5-MHz receive mode)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fundamental imaging at 2.0 MHz
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fundamental imaging at 3.5 MHz
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Harmonic imaging
Number of subjects: 29
Study: 7649071

Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal of trihexyphenidyle (group I)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Progressive withdrawal of trihexyphenidyle for 2 weeks (group II)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Continued treatment with trihexyphenidyle (group III)
Number of subjects: 101
Study: 2539772

Group type: EXPERIMENTAL
Intervention: Thymostimulin (1 mg/Kg i.m., days 7-14 of every cycle)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (without thymostimulin)
Number of subjects: 26
Study: 334808

Group type: EXPERIMENTAL
Intervention: Phenytoin 100 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Phenytoin 100 mg every 8 hours for two weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 20
Study: 31382986

Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 26865602

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg twice a day for 2 months with prayer (group B)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Propranolol 40 mg twice a day for 2 months (group A)
Number of subjects: 92
Study: 25730171

Group type: EXPERIMENTAL
Intervention: Mintz bibliotherapy intervention
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hall self-help book
Number of subjects: 45

Group type: COMPARATOR
Intervention: Wait-list control (WLC) group
Number of subjects: 45
Study: 23608721

Group type: EXPERIMENTAL
Intervention: 200 IU of daily vitamin D3
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 1,000 IU of daily vitamin D3
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 56
Study: 21875209

Group type: EXPERIMENTAL
Intervention: Expressive writing intervention group
Number of subjects: 179

Group type: COMPARATOR
Intervention: Control group (neutral writing)
Number of subjects: 179
Study: 19793473

Group type: EXPERIMENTAL
Intervention: Cefazolin 1g intravenously after induction of anesthesia (group 1)
Number of subjects: 144

Group type: COMPARATOR
Intervention: No prophylactic antibiotics (group 2)
Number of subjects: 144
Study: 16455437

Group type: EXPERIMENTAL
Intervention: Story-centered care
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard lifestyle intervention
Number of subjects: 24
Study: 12958610

Group type: EXPERIMENTAL
Intervention: Triacylglycerol infusion [1.5 ml/min]/heparin [0.2 IU/(kg.min)] (LIP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline only (SAL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline/heparin (HEP)
Number of subjects: 10
Study: 11200830

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20
Study: 9177404

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Calcium Supplementation (CS; 500 mg/day)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Calcium Supplementation (CS)
Number of subjects: 236
Study: 1447382

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine rinse (positive control)
Number of subjects: 15

Group type: COMPARATOR
Intervention: saline rinse (negative control)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sanguinarine rinse
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sanguinarine rinse with zinc
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Triclosan/SLS rinses
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Natural product/SLS experimental rinse
Number of subjects: 15
Study: 3522483

Group type: EXPERIMENTAL
Intervention: Low doses of acetylsalicylic acid
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 31078956

Group type: EXPERIMENTAL
Intervention: Poor sleep efficiency
Number of subjects: 338

Group type: COMPARATOR
Intervention: Apnea-hypopnea index (AHI)
Number of subjects: 338

Group type: COMPARATOR
Intervention: Sleep quality
Number of subjects: 338
Study: 29092985

Group type: EXPERIMENTAL
Intervention: Uncemented peri-apatite-coated TKA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cemented TKA
Number of subjects: 60
Study: 26387144

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 4922

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4922
Study: 23620943

Group type: EXPERIMENTAL
Intervention: TCM herbal cupping therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Thermal compressing therapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Mecobalamine (western medicine)
Number of subjects: 57
Study: 21480107

Group type: EXPERIMENTAL
Intervention: 10 μg of hepatitis B vaccine intramuscularly at birth (0), 2 and 9‐12 months of life
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine at 0, 1 and 6 months of life
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 64
Study: 19149069

Group type: EXPERIMENTAL
Intervention: Round bar design with resilient anchorage (group 1)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Milled bar design with rigid anchorage (group 2)
Number of subjects: 51
Study: 16492925

Group type: EXPERIMENTAL
Intervention: Highest quartile of energy intake (> or = 2,084 kcal/d)
Number of subjects: 38660

Group type: EXPERIMENTAL
Intervention: Current body mass index (BMI >30 kg/m2)
Number of subjects: 38660

Group type: COMPARATOR
Intervention: Vigorous recreational physical activity (> or = 4 hours/wk)
Number of subjects: 38660

Group type: EXPERIMENTAL
Intervention: Unfavorable energy balance (highest energy intake, highest BMI, least physical activity)
Number of subjects: 38660
Study: 14633652

Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 11737121

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg once daily)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg once daily)
Number of subjects: 154
Study: 9438490

Group type: EXPERIMENTAL
Intervention: 0.16 ppm ozone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 8
Study: 8249784

Group type: COMPARATOR
Intervention: Control (nonpreconditioned) + vehicle
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control + DCF
Number of subjects: 4

Group type: COMPARATOR
Intervention: Preconditioned + vehicle
Number of subjects: 4

Group type: COMPARATOR
Intervention: Preconditioned + DCF
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Preconditioned groups (both vehicle and DCF)
Number of subjects: 4
Study: 3677969

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28796128

Group type: EXPERIMENTAL
Intervention: Cycle ergometer (Tabata protocol [TBT]; eight 20‐second bouts at 170% Pmax interspersed by 10‐second rest)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Whole-body calisthenic exercises (McRae protocol; eight 20‐second all‐out intervals interspersed by 10‐second rest)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cycle ergometer (Tabata protocol [TBT])
Number of subjects: 12
Study: 26784016

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 24576196

Group type: EXPERIMENTAL
Intervention: Titration (15 mcg/m(2) s.c. three times weekly during week 1, 30 mcg/m(2) s.c. three times weekly during week 2, followed by 50 mcg/m(2) s.c. three times weekly during week 3)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No Titration (full 50 mcg/m(2) s.c. three times weekly for 3 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Titration
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Titration and No Titration
Number of subjects: 40
Study: 23536105

Group type: EXPERIMENTAL
Intervention: Varenicline plus intensive smoking cessation counseling
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Bupropion SR plus intensive smoking cessation counseling
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo plus intensive smoking cessation counseling
Number of subjects: 294
Study: 21285475

Group type: EXPERIMENTAL
Intervention: Exercise program (3 sessions of 60 min/week for 8 weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study: 19595247

Group type: EXPERIMENTAL
Intervention: Sevoflurane (P(ET))
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Propofol (target effect site concentration)
Number of subjects: 200
Study: 16549837

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,250 mg/m2 on days 1 and 8 and cisplatin 80 mg/m2 on day 1 plus aprinocarsen 2 mg/kg/d as continuous infusion for 14 days
Number of subjects: 670

Group type: COMPARATOR
Intervention: Gemcitabine 1,250 mg/m2 on days 1 and 8 and cisplatin 80 mg/m2 on day 1
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Experimental arms (gemcitabine and cisplatin with aprinocarsen)
Number of subjects: 670
Study: 12735916

Group type: EXPERIMENTAL
Intervention: Lining with Revolution
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lining with Tetric Flow
Number of subjects: 40

Group type: COMPARATOR
Intervention: Restoration in bulk after cavity lining with flowable composites
Number of subjects: 40

Group type: COMPARATOR
Intervention: Restoration in two oblique layers of high-viscosity composites
Number of subjects: 40
Study: 10686267

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) with a 'figure eight' coil held in various positions over the left primary motor cortex.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Scalp sensation assessment with the coil in various positions over the prefrontal area.
Number of subjects: 9
Study: 9266531

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 administered as a meal (30 mg/person)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 administered as capsules (30 mg/person)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coenzyme Q10 (both forms of administration)
Number of subjects: 0
Study: 8141183

Group type: EXPERIMENTAL
Intervention: AN69 dialyzer
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cuprophane or polysulfone dialyzers
Number of subjects: 10
Study: 3440392

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 4524

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 4524
Study: 29708775

Group type: EXPERIMENTAL
Intervention: Playing exergames (Xbox 360, 30 minutes once a week for 2 weeks)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control group (no exergame participation)
Number of subjects: 337
Study: 27570178

Group type: EXPERIMENTAL
Intervention: VIP programme (intervention group)
Number of subjects: 2834

Group type: COMPARATOR
Intervention: Standard health education curriculum (control group)
Number of subjects: 2834
Study: 25254614

Group type: EXPERIMENTAL
Intervention: In-school intervention based on compassion, self-efficacy, emotional well-being, peer and parental support, delivered in 10 sessions.
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 1200
Study: 22158731

Group type: EXPERIMENTAL
Intervention: 7.5 mg phentermine/46 mg controlled-release topiramate (7.5/46)
Number of subjects: 676

Group type: EXPERIMENTAL
Intervention: 15 mg phentermine/92 mg controlled-release topiramate (15/92)
Number of subjects: 676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676
Study: 20308618

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI)
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (pPCI) among patients at referral hospitals
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Fibrinolysis among patients at referral hospitals
Number of subjects: 1572
Study: 18512557

Group type: EXPERIMENTAL
Intervention: 400 mg amikacin administered at 3-4 postburn hours (A group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 mg amikacin administered at 10 postburn hours (B group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 400 mg amikacin administered at 20 postburn hours (C group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 400 mg amikacin administered at 30 postburn hours (D group)
Number of subjects: 20
Study: 21190790

Group type: EXPERIMENTAL
Intervention: BEV+IFN
Number of subjects: 628

Group type: COMPARATOR
Intervention: Interferon alone
Number of subjects: 628

Group type: COMPARATOR
Intervention: Motzer criteria
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Comparison of the novel model and Motzer criteria
Number of subjects: 628
Study: 16214627

Group type: EXPERIMENTAL
Intervention: Round incisors (evaluated by restorative dentists)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Round and square‐round incisors (evaluated by orthodontists)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Square‐round incisors (evaluated by all groups)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Female images rated by male judges
Number of subjects: 335
Study: 12100328

Group type: EXPERIMENTAL
Intervention: Na-P preparation
Number of subjects: 50

Group type: COMPARATOR
Intervention: PEG preparation
Number of subjects: 50
Study: 9842950

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride (titrated to a maximum of 200 mg/d for 12 weeks)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Sertraline hydrochloride
Number of subjects: 187
Study: 8128938

Group type: EXPERIMENTAL
Intervention: IV bolus of p‐aminohippurate (PAH) 10 mg/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: IV bolus of phenolsulfonphthalein (PSP) 1 mg/kg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard constant‐rate IV infusion of PAH
Number of subjects: 8
Study: 2918184

Group type: EXPERIMENTAL
Intervention: Hyposensitization therapy with Gi-rep (MW 106,000)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyposensitization therapy with Ei-M (MW 22,800)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyposensitization therapy with DIIIa (MW 9980)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyposensitization therapy (all antigens)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ei-M-specific IgG titer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ei-M-specific IgE titer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyposensitization therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DIIIa
Number of subjects: 0
Study: 791105

Group type: EXPERIMENTAL
Intervention: mannitol (M), 1 g/kg
Number of subjects: 11

Group type: COMPARATOR
Intervention: amphotericin B, 1 mg/kg
Number of subjects: 11
Study: 11557169

Group type: EXPERIMENTAL
Intervention: Physostigmine augmentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scopolamine antagonism of physostigmine's action
Number of subjects: 0

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 0
Study: 31055010

Group type: EXPERIMENTAL
Intervention: Beetroot/carrot bar (B/C), n=45
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Pumpkin/sweet potato bar (P/S), n=44
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Boredom Group (beetroot/carrot bar at high frequency), n=47
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Neutral bar (no vegetables), n=46
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control Group, n=40
Number of subjects: 256
Study: 29855372

Group type: EXPERIMENTAL
Intervention: Alpha Brain nootropic supplement (1925 mg, 3 pills per day: 2 pills at breakfast, 1 pill at dinner)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Alpha Brain nootropic supplement
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 27694266

Group type: EXPERIMENTAL
Intervention: DOAC early (started ≤7 days after event)
Number of subjects: 204

Group type: COMPARATOR
Intervention: DOAC late (started >7 days after event)
Number of subjects: 204

Group type: COMPARATOR
Intervention: VKA (Vitamin K Antagonists)
Number of subjects: 204
Study: 24529654

Group type: EXPERIMENTAL
Intervention: Adhesive use during the first 15 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: No use of adhesive during the first 15 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adhesive use influenced the area covered with biofilm on the internal surfaces of the complete dentures
Number of subjects: 30
Study: 22035647

Group type: EXPERIMENTAL
Intervention: Preoperative counseling (Treatment group)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (no preoperative counseling)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Reference group (consented but did not participate in counseling)
Number of subjects: 141
Study: 20136176

Group type: EXPERIMENTAL
Intervention: Cochlear implant (CI) listeners
Number of subjects: 2

Group type: COMPARATOR
Intervention: Normally hearing (NH) listeners
Number of subjects: 2
Study: 17374708

Group type: COMPARATOR
Intervention: iv bolus endotoxin [lipopolysaccharide (LPS), 3 ng/kg]
Number of subjects: 20